Recently, Sino Biopharmaceutical Limited (1177.HK) officially released the "Green Supply Chain Initiative", fully engaging with industry chain partners.

On June 6, the "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum was held at the Chia Tai Tianqing Global R&D Headquarters in Minhang District, Shanghai.

Recently, the American magazine Time, in collaboration with the globally renowned data statistics agency Statista, released the inaugural "The World’s Most Impactful Companies" list.

IDH1 inhibitors are an important component of precision therapy for biliary tract cancer, but currently, no drug targeting this pathway has been approved for the treatment of biliary tract cancer in China. On May 28, TQB3454, an IDH1 inhibitor independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical (1177.HK), was officially included in the priority review and approval process.

On May 29, the official website of the National Medical Products Administration (NMPA) showed that Naldemedine (generic name: Naldemedine Tosilate tablets, trade name: Symproic®) was approved for marketing for the treatment of opioid-induced constipation (OIC) in adults.

On May 28, GlaxoSmithKline (LSE/NYSE: GSK) announced positive pivotal data for bepirovirsen, an antisense oligonucleotide (ASO) drug for the treatment of chronic hepatitis B (CHB). The results of two Phase III clinical trials, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) Congress. On May 11, Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical (1177.HK), entered into an exclusive strategic cooperation with GlaxoSmithKline (GSK) to accelerate the marketing process of bepirovirsen in China.

Recently, S&P Global, an internationally authoritative sustainability assessment agency, held the launch ceremony for "The Sustainability Yearbook" (China Edition) 2026 in Shanghai.

Recently, the preclinical and Phase I clinical results of TQB2102 (a HER2 bispecific-bispecific ADC), a first-in-class (FIC) new drug independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical (1177.HK), for the treatment of advanced solid tumors, were published online in Annals of Oncology (impact factor 65.4), the flagship journal of the European Society for Medical Oncology (ESMO). This study, led by the team of Academician Xu Ruihua and Professor Wang Shusen from Sun Yat-sen University Cancer Center, for the first time systematically released the efficacy and safety data of TQB2102 from human clinical studies, and simultaneously disclosed its preclinical research results, confirming the differentiated characteristics of TQB2102 as a bispecific HER2 ADC.

In the field of advanced gastric cancer, CLDN18.2 is the second hot target after HER2 to have its druggability validated, with approximately 38.4% of gastric cancer patients showing high expression of CLDN18.2. On May 22, the CLDN18.2 ADC, Tecotabart Vedotin Monoclonal Antibody for Injection (LM-302), independently developed by LaNova Medicines, a core enterprise of Sino Biopharmaceutical (1177.HK), and submitted by Shanghai Chia Tai Tianqing, was officially included in the priority review and approval process.

On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical (1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.